Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy

ClinicalTrials.gov ID: NCT00693329

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00693329. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center clinical study designed to assess the performance of the Triage NGAL test as an aid in the early risk assessment for contrast-induced nephropathy (CIN). Approximately 260 adults at risk for CIN undergoing intra-arterial angiography involving administration of iodinated contrast agent(s) will be enrolled.

Study identification

NCT ID: NCT00693329
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Abbott RDx Cardiometabolic; Other
Enrollment: 260 participants

Conditions and interventions

Conditions

Cardiovascular Surgery With Coronary Angiography

Interventions

Not listed

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2008 (Type not available)
Primary completion: Jun 2009 (Actual)
Completion: Dec 2009 (Actual)
Last update posted: Dec 18, 2009

2008 – 2009

United States locations

U.S. sites: 3
U.S. states: 1
U.S. cities: 3

Facility	City	State	ZIP	Site status
Cardiac and Vascular Research Center of Northern Michigan	Petoskey	Michigan	49770	—
Providence Hospital	Providence	Michigan	48075	—
William Beaumont Hospital	Royal Oak	Michigan	48073	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00693329, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2009 · Synced Nov 14, 2026